Search research articles
Contact Us
Filters
Showing results (71-80 of 77) with videos related to
Page
of 8
Sort By:
You have reached the last page of results.
This site can display upto 77 results.
Nature Medicine
|
January 10, 2017
Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
Arnab Ghosh, Melody Smith, Scott E James, et al.
Cell Reports
|
November 8, 2023
The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability
Niklas Ravn-Boess, Nainita Roy, Takamitsu Hattori, et al.
Bone Marrow Transplantation
|
May 11, 2026
Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma
Laura B Oswald, Xiaoyin Li, Lisa M Gudenkauf, et al.
Blood Advances
|
January 21, 2026
Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicity
Laura B Oswald, Xiaoyin Li, Carina E Ferraris, et al.
Blood
|
June 20, 2026
Expanded antigen-specific donor regulatory T cells for GVHD prevention
Joseph A Pidala, Nicoletta Cieri, Michael J Schell, et al.
Haematologica
|
July 10, 2025
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma
Danai Dima, Jennifer M Logue, Syed Hamza Bin Waqar, et al.
Blood
|
June 11, 2026
Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma
Jerald D Noble, Barbara C Peixoto, Meghan A Menges, et al.
Page
of 8
Search research articles
Search
Showing results (71-80 of 77) with videos related to
Sort By:
Page
of 8
You have reached the last page of results.
This site can display upto 77 results.
Nature Medicine
|
January 10, 2017
Donor CD19 CAR T cells exert potent graft-versus-lymphoma activity with diminished graft-versus-host activity
Arnab Ghosh, Melody Smith, Scott E James, et al.
Cell Reports
|
November 8, 2023
The expression profile and tumorigenic mechanisms of CD97 (ADGRE5) in glioblastoma render it a targetable vulnerability
Niklas Ravn-Boess, Nainita Roy, Takamitsu Hattori, et al.
Bone Marrow Transplantation
|
May 11, 2026
Patient-reported outcomes after idecabtagene vicleucel vs. ciltacabtagene autoleucel CAR-T for multiple myeloma
Laura B Oswald, Xiaoyin Li, Lisa M Gudenkauf, et al.
Blood Advances
|
January 21, 2026
Meaningful change in patient-reported outcomes after CAR-T for multiple myeloma: Differences by race and ethnicity
Laura B Oswald, Xiaoyin Li, Carina E Ferraris, et al.
Blood
|
June 20, 2026
Expanded antigen-specific donor regulatory T cells for GVHD prevention
Joseph A Pidala, Nicoletta Cieri, Michael J Schell, et al.
Haematologica
|
July 10, 2025
Cytopenias and infections following ciltacabtagene autoleucel in heavily-pretreated relapsed or refractory multiple myeloma
Danai Dima, Jennifer M Logue, Syed Hamza Bin Waqar, et al.
Blood
|
June 11, 2026
Product-Intrinsic NF-κB-Driven Transcriptional Programs Connote Durability of CAR-T Response in Multiple Myeloma
Jerald D Noble, Barbara C Peixoto, Meghan A Menges, et al.
Page
of 8